The DOI matches its Crossref record; 178 of the 180 references it cites were found in a registry or an index.
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Open accessAbstract
Approximately 50% of epithelial ovarian cancers (EOC) exhibit defective DNA repair via homologous recombination (HR) due to genetic and epigenetic alterations of HR pathway genes. Defective HR is an important therapeutic target in EOC as exemplified by the efficacy of platinum analogues in this disease, as well as the advent of PARP inhibitors, which exhibit synthetic lethality when applied to HR-deficient cells. Here, we describe the genotypic and phenotypic characteristics of HR-deficient EOCs, discuss current and emerging approaches for targeting these tumors, and present challenges associated with these approaches, focusing on development and overcoming resistance. Significance: Defective DNA repair via HR is a pivotal vulnerability of EOC, particularly of the high-grade serous histologic subtype. Targeting defective HR offers the unique opportunity of exploiting molecular differences between tumor and normal cells, thereby inducing cancer-specific synthetic lethality; the promise and challenges of these approaches in ovarian cancer are discussed in this review. Cancer Discov; 5(11); 1137–54. ©2015 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Increasing evidence suggests that tumors with HR deficiency are more likely to be highly sensitive to platinum-based chemotherapy20–22.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
The resurgence of platinum-based cancer chemotherapy
Kèlland, L. R. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2167 · Cited by 4,733
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke‐Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,798
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B. N., Wenzel, L. B., Huang, H. Q., Baergen, R. N., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,626
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Cited by
Sorted by citations
Items 101–200 of 946
Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer
Kraya, A., Maxwell, K. N., Wubbenhorst, B. S., Wenz, B. M., Pluta, J. B., Rech, A. J., Dorfman, L. M., Lunceford, N., Barrett, A., Mitra, N., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0468 · Cited by 101
MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer
Yi, J., Liu, C., Tao, Z., Wang, M., Jia, Y., Sang, X., Shen, L., Xue, Y., Jiang, K., Luo, F., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.027 · Cited by 99
Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
Ledermann, J. A., & Pujade-Lauraine, É. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919849753 · Cited by 101
Zhang, X., Yao, J., Li, X., Niu, N., Liu, Y., Hajek, R. A., Peng, G., Westin, S. N., Sood, A. K., & Liu, J. (2023) · Science Advances · doi:10.1126/sciadv.adf7195 · Cited by 101
Achieving Precision Death with Cell-Cycle Inhibitors that Target DNA Replication and Repair
Bence, A. K., McNeely, S., & Beckmann, R. P. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0083 · Cited by 91
Homologous recombination proficiency in ovarian and breast cancer patients
Creeden, J. F., Nanavaty, N. S., Einloth, K. R., Gillman, C. E., Stanbery, L., Hamouda, D., Dworkin, L. D., & Nemunaitis, J. J. (2021) · BMC Cancer · doi:10.1186/s12885-021-08863-9 · Cited by 96
Paffenholz, S. V., Salvagno, C., Ho, Y.-J., Limjoco, M., Baslan, T., Tian, S., Kulick, A. R., de Stanchina, E., Wilkinson, J. E., Barriga, F. M., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2117754119 · Cited by 93
Increased oxidative stress mediates the antitumor effect of PARP inhibition in ovarian cancer
Hou, D., Liu, Z., Xu, X., Liu, Q., Zhang, X., Kong, B., Wei, J., Gong, Y., & Shao, C. (2018) · Redox Biology · doi:10.1016/j.redox.2018.03.016 · Cited by 90
Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer
Lee, E. K., & Konstantinopoulos, P. A. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.06.004 · Cited by 89
Self-citationLheureux, S., Bruce, J. P., Burnier, J. V., Karakasis, K., Shaw, P. A., Clarke, B. A., Yang, S. Y. C., Quevedo, R., Li, T., Dowar, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3677 · Cited by 92
Zhang, S., Iyer, S., Ran, H., Dolgalev, I., Gu, S. S., Wei, W., Foster, C., Loomis, C. A., Olvera, N., Dao, F., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0455 · Cited by 89
High-throughput approaches for precision medicine in high-grade serous ovarian cancer
Govindarajan, M., Wohlmuth, C., Waas, M., Bernardini, M. Q., & Kislinger, T. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00971-6 · Cited by 89
Actionable gene-based classification toward precision medicine in gastric cancer
Ichikawa, H., Nagahashi, M., Shimada, Y., Hanyu, T., Ishikawa, T., Kameyama, H., Kobayashi, T., Sakata, J., Yabusaki, H., Nakagawa, S., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0484-3 · Cited by 87
Homologous Recombination Deficiency in Breast Cancer: A Clinical Review
den Brok, W. D., Schrader, K. A., Sun, S. B., Tinker, A. V., Stutheit-Zhao, E. Y., Aparicio, S. A. J. R., & Gelmon, K. A. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00031 · Cited by 86
Maximizing Synergistic Activity When Combining RNAi and Platinum-Based Anticancer Agents
Xiao, H., Qi, R., Li, T., Awuah, S. G., Zheng, Y., Wei, W., Kang, X., Song, H., Wang, Y., Yu, Y., et al. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.6b12108 · Cited by 83
Mechanism of PARP inhibitor resistance and potential overcoming strategies
Fu, X., Li, P., Zhou, Q., He, R., Wang, G., Zhu, S., Bagheri, A., Kupfer, G. M., Pei, H., & Li, J. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.02.014 · Cited by 89
Regulation and pharmacological targeting of RAD51 in cancer
Grundy, M. K., Buckanovich, R. J., & Bernstein, K. A. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa024 · Cited by 85
Hoskins, P. J., & Gotlieb, W. H. (2017) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21408 · Cited by 77
Hurley, R. M., Hendrickson, A. E. W., Visscher, D. W., Ansell, P. J., Harrell, M. I., Wagner, J. M., Negron, V. C., Goergen, K. M., Maurer, M. J., Oberg, A. L., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.01.015 · Cited by 76
Aberrations in DNA repair pathways in cancer and therapeutic significances
Motegi, A., Masutani, M., Yoshioka, K., & Bessho, T. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.02.005 · Cited by 76
Patel, M. A., Nowsheen, S., Maraboyina, S., & Xia, F. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00390-7 · Cited by 78
Wilson, R. H., Evans, T. J., Middleton, M. R., Molife, L. R., Spicer, J. F., Dieras, V. C., Roxburgh, P., Giordano, H., Jaw‐Tsai, S., Goble, S. M., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.36 · Cited by 78
Targeting DNA repair and replication stress in the treatment of ovarian cancer
Murai, J. (2017) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1145-7 · Cited by 75
Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
Dockery, L., Gunderson, C., & Moore, K. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s114714 · Cited by 78
PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies
Lee, E. K., & Matulonis, U. A. (2020) · Cancers · doi:10.3390/cancers12082054 · Cited by 74
Topoisomerases and cancer chemotherapy: recent advances and unanswered questions
Bjornsti, M., & Kaufmann, S. H. (2019) · F1000Research · doi:10.12688/f1000research.20201.1 · Cited by 74
PARP inhibitors in ovarian cancer: An overview of the practice‐changing trials
Foo, T., George, A. J., & Banerjee, S. N. (2020) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22935 · Cited by 73
Batalini, F., Xiong, N., Tayob, N., Polak, M. M., Eismann, J., Cantley, L. C., Shapiro, G. I., Adalsteinsson, V. A., Winer, E. P., Konstantinopoulos, P. A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3045 · Cited by 73
Self-citationSerra, V., Wang, A. T., Castroviejo‐Bermejo, M., Polanska, U. M., Palafox, M., Herencia-Ropero, A., Jones, G. N., Lai, Z., Armenia, J., Michopoulos, F., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0568 · Cited by 74
Meghani, K. A., Fuchs, W., Detappe, A., Drané, P., Gogola, E., Rottenberg, S., Jonkers, J., Matulonis, U. A., Swisher, E. M., Konstantinopoulos, P. A., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.038 · Cited by 73
Self-citationNew Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
Han, Y., Yu, X., Li, S., Tian, Y. E., & Liu, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.578095 · Cited by 73
Zhou, Q., Huang, J., Zhang, C., Zhao, F., Kim, W., Tu, X., Zhang, Y., Nowsheen, S., Zhu, Q., Deng, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16443-x · Cited by 71
Recent Insights into Mucinous Ovarian Carcinoma
Ricci, F., Affatato, R., Carrassa, L., & Damia, G. L. M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061569 · Cited by 71
Kanakkanthara, A., Kurmi, K., Ekstrom, T. L., Hou, X., Purfeerst, E. R., Heinzen, E. P., Correia, C., Huntoon, C. J., O’Brien, D. R., Hendrickson, A. E. W., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1405 · Cited by 71
Lee, E. K., & Konstantinopoulos, P. A. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920944116 · Cited by 72
Self-citationBiomarkers in ovarian cancer: To be or not to be
Arend, R. C., Martínez, A., Szul, T., & Birrer, M. J. (2019) · Cancer · doi:10.1002/cncr.32595 · Cited by 70
Homologous recombination deficiency real-time clinical assays, ready or not?
Fuh, K. C., Mullen, M. M., Blachut, B., Stover, E. H., Konstantinopoulos, P. A., Liu, J. F., Matulonis, U. A., Khabele, D., Mosammaparast, N., & Vindigni, A. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.08.035 · Cited by 73
Self-citationPignochino, Y., Capozzi, F., D’Ambrosio, L., Dell’Aglio, C., Basiricò, M., Canta, M., Lorenzato, A., Lutati, F. V., Aliberti, S., Palesandro, E., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0652-5 · Cited by 72
Wang, H., Shan, Z., Song, L., Qu, M., & Zou, Z. (2020) · Oncogene · doi:10.1038/s41388-020-1191-x · Cited by 72
Konstantinopoulos, P. A., da Costa, A. A. B. A., Gulhan, D., Lee, E. K., Cheng, S., Hendrickson, A. E. W., Kochupurakkal, B. S., Kolin, D. L., Kohn, E. C., Liu, J. F., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25904-w · Cited by 69
Self-citationZhu, L., Liu, J., Chen, J., & Zhou, Q. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01218-8 · Cited by 71
Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development
Angius, G., Tomao, S., Stati, V., Vici, P., Bianco, V., & Tomao, F. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03950-y · Cited by 69
Genetic predisposition to prostate cancer
Benafif, S., & Eeles, R. A. (2016) · British Medical Bulletin · doi:10.1093/bmb/ldw039 · Cited by 75
PARP mediated DNA damage response, genomic stability and immune responses
Zong, C., Zhu, T., He, J., Huang, R., Jia, R., & Shen, J. (2021) · International Journal of Cancer · doi:10.1002/ijc.33918 · Cited by 70
Konstantinopoulos, P. A., Lee, J., Gao, B., Miller, R. E., Lee, J., Colombo, N., Vergote, I. B., Credille, K. M., Young, S. R. L., McNeely, S., et al. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2022.09.019 · Cited by 67
Self-citationCadzow, L., Brenneman, J. B., Tobin, E. R., Sullivan, P., Nayak, S. U., Ali, J. A., Shenker, S., Griffith, J., McGuire, M. S., Grasberger, P. E., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0293 · Cited by 68
Tassi, R. A., Todeschini, P., Siegel, E. R., Calza, S., Cappella, P., Ardighieri, L., Cadei, M., Bugatti, M., Romani, C., Bandiera, E., et al. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0536-y · Cited by 67
Mutter, R. W., Riaz, N., Ng, C. K. Y., Delsite, R., Piscuoglio, S., Edelweiss, M., Martelotto, L. G., Sakr, R. A., King, T. A., Giri, D. D., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4890 · Cited by 68
Ruiz de Porras, V., Font, A., & Aytes, A. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.033 · Cited by 65
Targeting the tumour microenvironment in platinum-resistant ovarian cancer
Cummings, M., Freer, C., & Orsi, N. M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.007 · Cited by 65
Tang, S., Shen, Y., Wei, X., Shen, Z., Lü, W., & Xu, J. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05257-y · Cited by 68
Kwon, Y., Rösner, H. I., Zhao, W., Selemenakis, P., He, Z., Kawale, A. S., Katz, J. N., Rogers, C. M., Neal, F. E., Shabestari, A. B., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36211-x · Cited by 67
Konstantinopoulos, P. A., Lheureux, S., & Moore, K. N. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_288015 · Cited by 65
Self-citationBreast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches
Schick, J., Ritchie, R. P., & Restini, C. B. A. (2021) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223421995854 · Cited by 64
de Jonge, M. M., Mooyaart, A. L., Vreeswijk, M. P. G., de Kroon, C. D., van Wezel, T., van Asperen, C. J., Smit, V. T. H. B. M., Dekkers, O. M., & Bosse, T. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.11.028 · Cited by 64
Maintenance therapy for newly diagnosed epithelial ovarian cancer– a review
Nag, S. M., Aggarwal, S., Rauthan, A., & Warrier, N. E. (2022) · Journal of Ovarian Research · doi:10.1186/s13048-022-01020-1 · Cited by 64
Sisay, M., & Edessa, D. (2017) · Gynecologic Oncology Research and Practice · doi:10.1186/s40661-017-0055-8 · Cited by 63
Veneris, J. T., Matulonis, U. A., Liu, J. F., & Konstantinopoulos, P. A. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.09.021 · Cited by 62
Self-citationLønning, P. E., Nikolaienko, O., Pan, K., Kurian, A. W., Eikesdal, H. P., Pettinger, M. B., Anderson, G. L., Prentice, R. L., Chlebowski, R. T., & Knappskog, S. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.3846 · Cited by 62
Garcinone E induces apoptosis and inhibits migration and invasion in ovarian cancer cells
Xu, X.-H., Liu, Q.-Y., Li, T., Liu, J., Chen, X., Huang, L., Qiang, W., Chen, X., Wang, Y., Lin, L., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11417-4 · Cited by 62
Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer
Vanderstichele, A., Busschaert, P., Olbrecht, S., Lambrechts, D., & Vergote, I. B. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.08.029 · Cited by 62
Nero, C., Vizzielli, G., Lorusso, D., Cesari, E., Daniele, G., Loverro, M., Scambia, G., & Sette, C. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01917-7 · Cited by 59
Cen, Y., Fang, Y., Ren, Y., Hong, S., Lü, W., & Xu, J. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04807-8 · Cited by 58
Menghi, F., Banda, K., Kumar, P., Straub, R., Dobrolecki, L. E., Rodriguez, I. V., Yost, S. E., Chandok, H., Radke, M. R., Zhu, A. S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn1926 · Cited by 58
Diagnostic and prognostic potential of the microbiome in ovarian cancer treatment response
Asangba, A. E., Chen, J., Goergen, K. M., Larson, M. C., Oberg, A. L., Casarin, J., Multinu, F., Kaufmann, S. H., Mariani, A., Chia, N., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-27555-x · Cited by 59
Matulonis, U. A., & Monk, B. J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw697 · Cited by 57
How, J., Jazaeri, A. A., Fellman, B. M., Daniels, M. S., Penn, S., Solimeno, C., Yuan, Y., Schmeler, K. M., Lanchbury, J. S. S., Timms, K. M., et al. (2021) · Cancers · doi:10.3390/cancers13050946 · Cited by 57
Mangogna, A., Munari, G., Pepe, F., Maffii, E., Giampaolino, P., Ricci, G., Fassan, M., Malapelle, U., & Biffi, S. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13020284 · Cited by 61
Inflammation and Immune Escape in Ovarian Cancer: Pathways and Therapeutic Opportunities
Liu, C., Yin, Q., Wu, Z., Li, W., Huang, J., Chen, B., Yang, Y., Zheng, X., Zeng, L., & Wang, J. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s503479 · Cited by 60
Herzog, T. J., Vergote, I. B., Gomella, L. G., Milenkova, T., French, T., Tonikian, R., Poehlein, C. H., & Hussain, M. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.10.021 · Cited by 57
p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell
Tessoulin, B., Eveillard, M., Lok, A., Chiron, D., Moreau, P., Amiot, M., Moreau‐Aubry, A., Gouill, S. L., & Pellat‐Deceunynck, C. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.03.001 · Cited by 55
Pathways and Mechanisms that Prevent Genome Instability in Saccharomyces cerevisiae
Putnam, C. D., & Kolodner, R. D. (2017) · Genetics · doi:10.1534/genetics.112.145805 · Cited by 56
Sugino, K., Tamura, R., Nakaoka, H., Yachida, N., Yamaguchi, M., Mori, Y., Yamawaki, K., Suda, K., Ishiguro, T., Adachi, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-54116-y · Cited by 54
Pantelidou, C., Jadhav, H., Kothari, A., Liu, R., Wulf, G. M., Guerriero, J. L., & Shapiro, G. I. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00471-5 · Cited by 53
Self-citationBiallelic tumour suppressor loss and DNA repair defects in de novo small‐cell prostate carcinoma
Chedgy, E. C. P., Vandekerkhove, G. R., Herberts, C., Annala, M., Donoghue, A., Sigouros, M., Ritch, E. J., Struss, W. J., Konomura, S., Liew, J., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5137 · Cited by 53
KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer
Wu, Y., Chen, S., Shao, Y. W., Su, Y., Li, Q., Wu, J., Zhu, J., Wen, H., Huang, Y., Zheng, Z., et al. (2023) · Advanced Science · doi:10.1002/advs.202304638 · Cited by 52
Reyes, H. D., Devor, E. J., Warrier, A., Newtson, A. M., Mattson, J. N., Wagner, V. M., Duncan, G. N., Leslie, K. K., & Bosquet, J. G. (2019) · Scientific Reports · doi:10.1038/s41598-019-54401-w · Cited by 52
Nero, C., Boldrini, L., Lenkowicz, J., Giudice, M. T., Piermattei, A., Inzani, F. S., Pasciuto, T., Minucci, A., Fagotti, A., Zannoni, G. F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911326 · Cited by 52
O’Malley, D. M., Oza, A. M., Lorusso, D., Aghajanian, C. A., Oaknin, A., Dean, A. P., Colombo, N., Weberpals, J. I., Clamp, A. R., Scambia, G., et al. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2022.08.021 · Cited by 51
Feng, Z., Шао, Д., Cai, Y., Bi, R., Ju, X., Chen, D., Song, C., Chen, X., Li, J., An, N., et al. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-023-01129-x · Cited by 51
Human papillomavirus and genome instability: from productive infection to cancer
Prati, B., Marangoni, B. E. M., & Boccardo, E. (2018) · Clinics · doi:10.6061/clinics/2018/e539s · Cited by 54
Lü, Z., Mao, W., Yang, H., Santiago‐O’Farrill, J. M., Rask, P. J., Mondal, J., Chen, H., Ivan, C., Liu, X., Liu, C., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci146471 · Cited by 50
Marth, C., Abreu, M. H., Andersen, K. K., Aro, K. M., Batarda, M. D. L., Boll, D., Ekmann‐Gade, A. W., Haltia, U., Hansen, J., Haug, A. J., et al. (2022) · Cancer · doi:10.1002/cncr.34350 · Cited by 50
Fumagalli, C., Betella, I., Ranghiero, A., Guerini‐Rocco, E., Bonaldo, G., Rappa, A., Vacirca, D., Colombo, N., & Barberis, M. C. P. (2022) · Pathologica · doi:10.32074/1591-951x-791 · Cited by 50
Stover, E. H., Baco, M. B., Cohen, O., Li, Y. Y., Christie, E. L., Bagul, M., Goodale, A., Lee, Y., Pantel, S., Rees, M. G., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-1243 · Cited by 49
“Most patients with HGSOC respond to surgery and combination chemotherapy with platinum and taxanes, but >80% eventually develop recurrent disease and chemotherapy resistance, for which few effective therapies exist (1).”
BackgroundInfluentialGadducci, A., & Guerrieri, M. E. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.04.006 · Cited by 51
Wang, T., Liu, W., Shen, Q., Tao, R., Li, C., Shen, Q., Lin, Y., Huang, Y., Yang, L., Xie, G., et al. (2023) · Cancer Science · doi:10.1111/cas.15961 · Cited by 52
Germline BRCA -Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity
de Jonge, M. M., Ritterhouse, L. L., de Kroon, C. D., Vreeswijk, M. P. G., Segal, J. P., Puranik, R., Hollema, H., Rookus, M. A., van Asperen, C. J., van Leeuwen, F. E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0848 · Cited by 48
Sahnane, N., Carnevali, I. W., Formenti, G., Casarin, J., Facchi, S., Bombelli, R., Lauro, E. D., Memoli, D., Salvati, A., Rizzo, F. M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249708 · Cited by 48
Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer
Zou, X.-L., Li, X., Ke, H., Zhang, G., Tang, Q., Yuan, J., Zhou, C.-J., Zhang, J., Zhang, R., & Chen, W.-Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.689076 · Cited by 48
Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine
Guo, C., Song, C., Zhang, J., Gao, Y., Qi, Y., Zhao, Z., & Yuan, C. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.11.017 · Cited by 47
Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery
Colombo, I., Karakasis, K., Sneha, S., & Oza, A. M. (2023) · Cancers · doi:10.3390/cancers15123220 · Cited by 47
Harrington, S. P., Wilson, A. J., Hirst, J. J., Roby, K. F., Fadare, O., Crispens, M. A., Beeghly-Fadiel, A. C., & Khabele, D. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.01.038 · Cited by 47
PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives
Musacchio, L., Caruso, G., Pisano, C., Cecere, S. C., Napoli, M. D., Attademo, L., Tambaro, R., Russo, D., Califano, D., Palaia, I., et al. (2020) · Cancer Management and Research · doi:10.2147/cmar.s221001 · Cited by 48
Ruiz-Schutz, V. C., Gomes, L. M., Mariano, R. C., de Almeida, D. V. P., Pimenta, J. M., Dal Molin, G. Z., Kater, F. R., Yamamura, R., Correa Neto, N. F., Maluf, F. C., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.06.012 · Cited by 46
Functions of Breast Cancer Predisposition Genes: Implications for Clinical Management
Yoshimura, A., Imoto, I., & Iwata, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137481 · Cited by 48
Pérez‐Villatoro, F., Oikkonen, J., Casado, J., Chernenko, A., Gulhan, D., Tumiati, M., Li, Y., Lavikka, K., Hietanen, S., Hynninen, J., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00339-8 · Cited by 46
Self-citationCorvigno, S., Wisman, G. B. A., Mezheyeuski, A., van der Zee, A. G. J., Nijman, H. W., Åvall-Lundqvist, E. H., Östman, A., & Dahlstrand, H. M. (2016) · Oncotarget · doi:10.18632/oncotarget.7613 · Cited by 48
PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues
Murthy, P., & Muggia, F. M. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.002 · Cited by 49
Yan, S., Xuan, J., Brajanovski, N., Tancock, M. R. C., Madhamshettiwar, P. B., Simpson, K. J., Ellis, S. L., Kang, J., Cullinane, C. M., Sheppard, K. E., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01158-z · Cited by 46
Metadata
- Authors
- Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D.
- Affiliations
- Harvard University (US)
- 2Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
- Corresponding author
- Konstantinopoulos, Panagiotis A.
- Venue
- Cancer Discovery
- Published
- 2015-11-01
- Volume
- 5
- Issue
- 11
- Pages
- 1137-1154
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC4631624
- OpenAlex
- W2179105349
- Cited by
- 945
- References
- 180
- Citations by year
- 2026: 67 · 2025: 97 · 2024: 109 · 2023: 126 · 2022: 115 · 2021: 102 · 2020: 100 · 2019: 74 · 2018: 74 · 2017: 54 · 2016: 27
- FWCI
- 5.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA090687, UM1CA186709, P50CA168504)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Keywords
- homologous recombination deficiency, epithelial ovarian cancer, DNA repair deficiency, PARP inhibitors, synthetic lethality, platinum analogues, high-grade serous ovarian cancer, drug resistance, targeted therapy
- MeSH terms
- Carcinoma, Ovarian Epithelial, Animals, Antineoplastic Combined Chemotherapy Protocols, Clinical Trials as Topic, DNA Repair, Female, Humans, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Phenotype, Genetic Variation, Signal Transduction, Biomarkers, Gene Expression Regulation, Neoplastic, Treatment Outcome, Drug Resistance, Neoplasm, Molecular Targeted Therapy, Homologous Recombination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
